Nothing Special   »   [go: up one dir, main page]

Yang et al., 2019 - Google Patents

Degradability and clearance of inorganic nanoparticles for biomedical applications

Yang et al., 2019

View PDF
Document ID
8031920239766508113
Author
Yang G
Phua S
Bindra A
Zhao Y
Publication year
Publication venue
Advanced Materials

External Links

Snippet

Inorganic nanoparticles with tunable and diverse properties hold tremendous potential in the field of nanomedicine, while having non‐negligible toxicity concerns in healthy tissues/organs that have resulted in their restricted clinical translation to date. In the past …
Continue reading at dr.ntu.edu.sg (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
    • A61K47/48853—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere
    • A61K47/48861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere the form being an inorganic particle, e.g. a ceramic particle, silica particle, ferrite, synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
    • A61K47/48853—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere
    • A61K47/48876—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere the form being a solid micro- or nanoparticle having no hollow or gas-filled core
    • A61K47/48884—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere the form being a solid micro- or nanoparticle having no hollow or gas-filled core the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANO-TECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANO-STRUCTURES; MEASUREMENT OR ANALYSIS OF NANO-STRUCTURES; MANUFACTURE OR TREATMENT OF NANO-STRUCTURES
    • B82Y5/00—Nano-biotechnology or nano-medicine, e.g. protein engineering or drug delivery
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANO-TECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANO-STRUCTURES; MEASUREMENT OR ANALYSIS OF NANO-STRUCTURES; MANUFACTURE OR TREATMENT OF NANO-STRUCTURES
    • B82Y30/00—Nano-technology for materials or surface science, e.g. nano-composites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules

Similar Documents

Publication Publication Date Title
Yang et al. Degradability and clearance of inorganic nanoparticles for biomedical applications
Zhao et al. Versatile types of organic/inorganic nanohybrids: from strategic design to biomedical applications
Wang et al. Inorganic nanomaterials with rapid clearance for biomedical applications
Magne et al. Graphene and its derivatives: understanding the main chemical and medicinal chemistry roles for biomedical applications
Piao et al. Designed fabrication of silica‐based nanostructured particle systems for nanomedicine applications
Fan et al. Catalytic nanomaterials toward atomic levels for biomedical applications: from metal clusters to single-atom catalysts
Cai et al. All‐in‐One nanomedicine: multifunctional single‐component nanoparticles for cancer theranostics
Qian et al. Manganese‐based functional nanoplatforms: Nanosynthetic construction, physiochemical property, and theranostic applicability
Singh et al. Progress in nanotheranostics based on mesoporous silica nanomaterial platforms
Du et al. Disulfide‐bridged organosilica frameworks: designed, synthesis, redox‐triggered biodegradation, and nanobiomedical applications
Cheng et al. Functional nanomaterials for phototherapies of cancer
Wu et al. Mesoporous silica nanoparticles as nanocarriers
Song et al. Functionalization of metal nanoclusters for biomedical applications
Lee et al. Photothermally controllable cytosolic drug delivery based on core–shell MoS2-porous silica nanoplates
Sana et al. Recent development in near infrared light-responsive polymeric materials for smart drug-delivery systems
Soliman et al. Incorporation of Ru (II) polypyridyl complexes into nanomaterials for cancer therapy and diagnosis
Fernandes et al. Multifunctional engineered mesoporous silica/inorganic material hybrid nanoparticles: Theranostic perspectives
Li et al. Biodegradable theranostic nanoplatforms of albumin-biomineralized nanocomposites modified hollow mesoporous organosilica for photoacoustic imaging guided tumor synergistic therapy
Biswas et al. Biomaterials for interfacing cell imaging and drug delivery: An overview
Chien et al. Advanced near‐infrared light‐responsive nanomaterials as therapeutic platforms for cancer therapy
Lu et al. BSA modified, disulfide-bridged mesoporous silica with low biotoxicity for dual-responsive drug delivery
Li et al. Functional dendrimer–gold nanoparticle hybrids for biomedical applications
US20190255101A1 (en) Differential tumor cell cytotoxicity via contact with coated cerium oxide nanoparticles
Kostiv et al. Peg-neridronate-modified NaYf4: GD3+, Yb3+, TM3+/NaGdf4 core–shell upconverting nanoparticles for bimodal magnetic resonance/optical luminescence imaging
Molaei Turmeric-derived gadolinium-doped carbon quantum dots for multifunctional fluorescence imaging and MRI contrast agent